XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
31.73
-0.02 (-0.06%)
Nov 24, 2025, 4:00 PM EST - Market closed
XOMA Royalty Revenue
XOMA Royalty had revenue of $13.13M in the quarter ending June 30, 2025, with 18.43% growth. This brings the company's revenue in the last twelve months to $12.77M, up 30.23% year-over-year. In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth.
Revenue (ttm)
$12.77M
Revenue Growth
+30.23%
P/S Ratio
8.10
Revenue / Employee
$3,623,538
Employees
13
Market Cap
393.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
| Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
| Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
| Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
| Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
| Dec 31, 2019 | 18.37M | 13.07M | 246.67% |
| Dec 31, 2018 | 5.30M | -47.39M | -89.94% |
| Dec 31, 2017 | 52.69M | 47.13M | 846.98% |
| Dec 31, 2016 | 5.56M | -49.88M | -89.97% |
| Dec 31, 2015 | 55.45M | 36.58M | 193.90% |
| Dec 31, 2014 | 18.87M | -16.59M | -46.78% |
| Dec 31, 2013 | 35.45M | 1.67M | 4.94% |
| Dec 31, 2012 | 33.78M | -24.41M | -41.95% |
| Dec 31, 2011 | 58.20M | 24.56M | 72.99% |
| Dec 31, 2010 | 33.64M | -64.79M | -65.82% |
| Dec 31, 2009 | 98.43M | 30.44M | 44.78% |
| Dec 31, 2008 | 67.99M | -16.27M | -19.31% |
| Dec 31, 2007 | 84.25M | 54.75M | 185.62% |
| Dec 31, 2006 | 29.50M | 10.83M | 58.01% |
| Dec 31, 2005 | 18.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XOMA News
- 3 days ago - XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 12 days ago - XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewsWire
- 5 weeks ago - XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement - GlobeNewsWire
- 7 weeks ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha
- 7 weeks ago - XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 2 months ago - ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - PRNewsWire
- 2 months ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 2 months ago - XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. - GlobeNewsWire